A smartphone displays the Tempus website, showing Data-driven precision medicine on a dark background.

AstraZeneca Extends Tempus AI Partnership with $200 Million Commitment as Analyst Weighs Multiples

Tempus AI Inc. (NYSE:TEM) and AstraZeneca Plc. (NASDAQ:AZN) on Monday amended their master services agreement, extending the partnership through Dec. 31, 2031, establishing a new five-year financial commitment period starting Jan. 1, 2027.

• Tempus AI stock is among today’s weakest performers. Why is TEM stock falling?

AstraZeneca Commits $200 Million to Tempus AI Through 2031

Under the amendment, AstraZeneca committed to spend $200 million on Tempus AI’s existing and future products and services during the renewal period, targeting $40 million annually.

According to an SEC filing, the agreement also includes a minimum annual spending commitment of $32 million.

If AstraZeneca’s cumulative spending falls short of $200 million by the end of 2031, the agreement will automatically extend by one year, through Dec. 31, 2032, to cover the shortfall.

AstraZeneca retains the right to terminate the agreement at any time. However, if it terminates before fulfilling its financial commitment, it will be required to pay Tempus AI the remaining shortfall.

Analyst Views Renewal as Evidence of Customer Retention

William Blair views the renewal as the most direct evidence yet that Tempus’s data business can hold a customer once the data is built into a pharma partner’s R&D process.

Analyst Matt Larew wrote that AstraZeneca was the first enterprise-wide data relationship, and it uses the data across its portfolio for decisions ranging from target selection to trial design.

William Blair reiterates the Market Perform rating on AstraZeneca.

Valuation Discount and Market Perform Rating

Larew wrote that shares trade at ~6x 2027 consensus sales, a discount to the peer average of around 10x and its own (limited) history as a public company.

This valuation discount comes despite the multitude of long-term shots on goal across the diagnostics and data businesses.

For multiple expansion to materialize, we expect investors will want to see additional positive proof points on recent M&A contributing to numbers and more clarity on the growth profile and durability of the data business.

In October, Tempus expanded its multi-year collaboration for intismeran autogene (V940/mRNA-4157) individualized neoantigen therapy (INT) combined with Keytruda (pembrolizumab) for completely resected stage IIB-IV melanoma and other cancer types.

Intismeran autogene is jointly developed by Moderna Inc. (NASDAQ:MRNA) and Merck & Co. Inc. (NYSE:MRK).

TEM Price Action: Tempus AI shares were down 3.83% to $61.19 at the time of publication on Thursday, according to Benzinga Pro data.

Photo: Piotr Swat / Shutterstock

Market News and Data brought to you by Benzinga APIs
Share this article